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To the Editor: Yung et al. 
reported in the April 2011 issue of 
Emerging Infectious Diseases on 
the epidemiologic characteristics of 
the nationwide mumps outbreak in 
England and Wales in 2004−2005 (1). 
The associated effect of disease was 
considerable, with >43,000 reported 
cases and >2,600 hospitalizations. 
Compared with the prevaccine era, 
the average age of infection was 
higher, with infection occurring 
mostly in older teenagers and young 
adults (2). Older age at infection is 
associated with a higher risk of certain 
complications, particularly orchitis 
(3). Yung et al. reported that among 
cases of mumps, previous mumps 
measles rubella (MMR) vaccination 
offered considerable protection 
against orchitis, meningitis, and 
hospitalization (1).
In the Netherlands, mumps 
vaccination, using a 2-dose schedule 
with the MMR vaccine against 
measles, mumps, and rubella, was 
introduced in 1987, including catch-
up vaccination of 3 birth cohorts 
(1983–1985). From birth cohort 1985 
onwards, the coverage of the fi rst 
and second dose of MMR has been 
consistently >92% (4). This coverage 
led to immediate control of mumps, 
with mumps related hospitalization 
dropping from 390 cases in 1987 to 11 
in 1990 (5).
However, a major reemergence 
of mumps in the Netherlands occurred 
during August 2007–May 2009, when 
a large genotype D mumps outbreak 
affected mainly unvaccinated 
persons with a religious objection 
to vaccination (6). Subsequently, a 
genotype G outbreak of mumps started 
at the end of 2009, affecting mainly 
vaccinated adolescents. The outbreak 
started among university students in 
different cities, with a sudden increase 
in transmission after a large party for 
students in early 2009 (7).
The Dutch Centre for Infectious 
Disease Control advised Municipal 
Health Services in January 2011 
to recommend MMR vaccination 
for university students who were 
unvaccinated or who had received 
only 1 dose of vaccine in the past. 
This policy was further implemented 
in the new academic year that began 
in August 2011. Information regarding 
the effectiveness of previous 
MMR vaccination against mumps 
complications is needed to support 
this policy and to predict the effect on 
mumps-related disease.
To study this policy, we 
analyzed mumps notifi cations in the 
Netherlands during December 1, 
2009–June 14, 2011. Notifi cations 
include information about vaccination 
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status and complications (e.g., orchitis, 
meningitis, encephalitis, pancreatitis). 
Vaccination status was confi rmed by 
checking the national vaccination 
register, the general practitioner or 
patients’ vaccination booklets. Vaccine 
effectiveness against complications 
and hospitalizations was estimated by 
using logistic regression, adjusting for 
age group and sex.
In the study period, 958 cases were 
reported, and 16 case-patients were 
hospitalized (1.9% of case-patients 
with a known hospitalization status; 
n = 842). The median age of case-
patients was 22 years (range 1–86 
years), and 58.7% were male. We 
had information on the vaccination 
status of 905 case-patients (94.5%). 
For this group, 68% of these 
vaccination statuses were confi rmed. 
Of the 905 case-patients, 16% were 
unvaccinated, and 10% and 68% had 
received 1 and 2 doses, respectively; 
6% were vaccinated at least once, 
but number of doses was unknown. 
Of case-patients with information 
on the occurrence of complications 
(95.7%, n = 917), 73 (8.0%) reported 
≥1 complication. Orchitis was by 
far the most frequently reported 
complication (66 case-patients, 11.8% 
of men). Other complications included 
pancreatitis (2, 0.2%), meningitis (3, 
0.3%), and thyroiditis (1, 0.1%).
Previous vaccination with 1 or 
2 doses reduced the risk for mumps 
orchitis among male mumps case-
patients >12 years of age by ≈70% 
(Table). This fi nding is consistent 
with that reported by Yung et al. 
(1). Because of a lower number 
of cases, we could not reliably 
estimate the effect of vaccination 
in preventing hospitalization and 
other complications. The estimated 
proportion of case-patients hos-
pitalized derived from the enhanced 
mumps surveillance by Yung et al. 
is remarkably similar to our estimate 
(3% and 2%, respectively). It is likely 
that we underestimated the overall 
effect of disease associated with this 
outbreak. Notifi cation is known to 
be incomplete and complications 
developing after the date of notifi cation 
are not included. However, because the 
reporting of complications is unlikely 
to be associated with vaccination 
status, we believe our estimates of the 
vaccine’s protective effects among 
cases of mumps are unbiased.
Whereas objection to vaccinate 
was the predominant cause for the 
2007–2009 mumps outbreak in the 
Netherlands, the current outbreak 
seems to be caused by secondary 
vaccine failure. Potential causes 
of this failure include waning of 
vaccine induced immunity, a relative 
mismatch between vaccine and 
outbreak strain, and intense social 
contact in the affected group (8). Our 
observations that orchitis was the most 
frequently reported complication, 
and that previous MMR vaccination 
considerably reduced the risk of 
orchitis among cases of mumps, are 
important to justify recommending 
mumps vaccination to unvaccinated 
persons.
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No. (%) cases with 
complications OR aOR† p value 
Adjusted VE,‡ % 
(95% CI) 
Orchitis§ 0 86 20 (23) Ref Ref Ref Ref
 1 48 5 (10) 0.38 0.34 0.05 66 (1 to 88)
 2 338 31 (9) 0.32 0.26 <0.01 74 (49 to 87)
Other complications¶ 0 117 1 (1) Ref Ref Ref Ref
 1 85 1 (1) 1.38 0.88 0.93 12 (–14 to 95)
 2 571 6 (1) 1.23 0.75 0.80 25 (–5 to 91)
Hospitalization 0 130 4 (3) Ref Ref Ref Ref
 1 83 2 (2) 0.80 0.70 0.69 30 (–312 to 88)
 2 535 6 (1) 0.40 0.43 0.25 57 (–84 to 90)
*Only those for whom complication and vaccination status were known are included; therefore, totals may differ. MMR, mumps, measles, rubella; OR, 
odds ratio; aOR, adjusted odds ratio; VE, vaccine effectiveness; ref, reference categories.  
†OR and VE adjusted for age group (<18, 18 25, >25 y) and sex, except for orchitis, where the OR and VE were adjusted only for age group. 
‡VE = 1 – OR where the OR is an approximation of the relative risk. 
§Only male patients 12 years of age are included. 
¶Includes the following reported complications: pancreatitis (n = 2), meningitis (3), thyroiditis (1), bronchitis (1), high fever and shortness of breath (1). 
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Genetic 
Characterization 
of Peste des Petits 
Ruminants Virus, 
Sierra Leone
To the Editor: Peste des 
petits ruminants (PPR) is a highly 
infectious disease of small ruminants, 
characterized by high rates of illness 
and death and caused by a single-
stranded RNA virus (peste des petits 
ruminants virus [PPRV]). PPRV can 
be divided into 4 genetically distinct 
lineages based on the nucleocapsid 
(N) gene (1). The lineages correlate 
well with geographic distribution of 
the virus, with lineages I and II mainly 
restricted to western and central 
Africa, lineage III to eastern Africa 
and the Arabian peninsula, and lineage 
IV to Southeast Asia, the Middle East, 
and more recently northern Africa (2).
PPRV is endemic to most of 
western Africa, and considered a 
major constraint on the livestock 
industry. In Sierra Leone, a country 
bordered by Guinea, Liberia, and 
the Atlantic Ocean, and having high 
goat and sheep populations, PPRV is 
believed to be the cause of outbreaks 
of respiratory disease with high 
death rates. Inadequate veterinary 
infrastructure and diagnostic capacity, 
exacerbated by the civil war in 
1991–2002, however, has prevented 
confi rmation. In this study, we 
confi rmed presence of PPRV in Sierra 
Leone, which led to the offi cial report 
of PPR to the World Organisation for 
Animal Health (Paris, France).
The study was conducted in April 
2009 as part of a training mission 
organized at Teko Central Veterinary 
Laboratory, Makeni, Sierra Leone, by 
the World Organisation for Animal 
Health Collaborating Centre for 
Biotechnology–based Diagnosis of 
Infectious Diseases in Veterinary 
Medicine (www.sva.se/oie-cc) in 
collaboration with the Food and 
Agriculture Organization–Emergency 
Center for Transboundary Animal 
Diseases, Bamako, Mali. During the 
training, blood and serum samples 
were collected from goats (n = 9) and 
sheep (n = 1) from 2 smallholders with 
suspected outbreaks of PPR in the 
area around Makeni in central Sierra 
Leone. In addition, serum from 5 goats 
with respiratory disease was sampled 
at a livestock market in Kabala 100 
km north of Makeni.
Serologic testing was performed 
at Teko. All serum samples (n = 15) 
were tested for PPRV antibodies by 
using a commercial ELISA (BDSL, 
Ayrshire, UK; 3); 12 (80%) of the 
samples were positive for PPRV.
Blood samples were collected on 
Nobuto fi lter strips (Advantec MFS 
Inc., Tokyo, Japan) and transported 
to the BioSafety Level 3 laboratory 
at the National Veterinary Institute, 
Uppsala, Sweden, for nucleic acid 
detection (4,5). RNA was eluted from 
the blood impregnated fi lter strips and 
screened for PPRV by using real-time 
RT-PCR specifi c for the N gene (6). 
Viral RNA was detected in 13 (87%) 
of the samples, with most of the 
positive samples indicating high viral 
load (cycle threshold <20).
For determination of the genetic 
lineage of detected viruses, RNA from 
all samples was subjected to PCR 
amplifi cation of a 351-bp segment 
of the N gene by using the NP3/NP4 
primer pair (7), but with a modifi ed 
protocol using the One-Step RT-PCR 
kit (QIAGEN, Hilden, Germany) 
(5). Amplifi ed PCR products were 
separated by electrophoresis, gel 
extracted, purifi ed, and processed 
for sequencing by using ABI PRISM 
BigDye Terminator v3.1 kit (Applied 
Biosystems, Foster City, CA, USA), 
according to the manufacturer’s 
instructions.
N gene sequences were obtained 
from 10 (67%) of the samples, and 
showed 83%–100% nt identity level 
compared with sequences available 
in GenBank using the BLASTn tool 
(www.ncbi.nlm.nih.gov/blast) and 
93%–100% identity between each 
other. Phylogenetic analysis was 
performed with 4 representative 
sequences (GenBank accession nos. 
JN602079–JN602082) from this study 
by using neighbor-joining and the 
Kimura 2-parameter model in MEGA5 
(CEMI, Tempe, AZ, USA), including 
N gene sequences representing all 4 
lineages.
The PPR viruses from Sierra 
Leone clustered in lineage II with 
viruses from Mali, Nigeria, and Ghana, 
and could further be distinguished into 
2 clusters (Figure). One virus from 
Kabala clustered closely with viruses 
from Mali (Mali 99/1), whereas all 
others showed 100% identity with 
a virus from Nigeria (Nig/75/1), in 
many countries used as vaccine virus 
strain. In Sierra Leone at the time, 
however, PPR vaccination was not 
being performed, suggesting that 
obtained sequences originated from 
circulating fi eld viruses related to 
Nig/75/1 rather than being vaccine 
derived. This suggestion was strongly 
supported by the clinical presentation 
typical of PPR. Surprisingly, no 
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